FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169396312> ?p ?o ?g. }

• W3169396312 abstract "Background and Purpose: The effect of Iguratimod in the treatment of rheumatoid arthritis was confirmed in past studies. In terms of the mechanism of the effect and clinical application experience, Iguratimod has a potential value in the treatment of spondyloarthritis (SpA). This study evaluated the efficacy and safety of Iguratimod on active SpA. Methods: Subjects with active SpA were enrolled and randomly divided into two groups at a ratio of 1:2 (placebo vs. Iguratimod). On the basis of non-steroidal anti-inflammatory drugs, combined treatment with Iguratimod or placebo, followed by follow-up every 4 weeks for 24 weeks. The primary efficacy endpoint was to evaluate the alleviation rate of ASAS20; the important improvement of ASDAS and the efficacy of spinal mobility, physical function and quality of life at the 24th week. Results: A total of 48 cases in the Iguratimod group and 25 cases in the placebo group were included in the final analysis. On the 24th week, the percentage of responders to ASAS20 (80 vs. 44%) and ASAS40 (56 vs. 20%) treated with Iguratimod were significantly higher than that in the placebo group ( P &lt; 0.05). Twelve cases had gastrointestinal discomfort, of which eight were in the Iguratimod group (16.7%, one case withdrew from the study due to diarrhoea) and four were in the placebo group (16.0%). No significant difference was found between the two groups ( P &lt; 0.05). Three cases of elevated transaminase were observed in the Iguratimod group and none in the placebo group, with no significant difference ( P &lt; 0.05). Conclusion: Iguratimod could significantly reduce the symptoms and signs of patients with active SpA. It could improve the physical function and quality of life of these patients and the overall safety and tolerance are good." @default.
• W3169396312 created "2021-06-22" @default.
• W3169396312 creator A5012912140 @default.
• W3169396312 creator A5014630057 @default.
• W3169396312 creator A5024129575 @default.
• W3169396312 creator A5027023070 @default.
• W3169396312 creator A5030777217 @default.
• W3169396312 creator A5039317523 @default.
• W3169396312 creator A5040219665 @default.
• W3169396312 creator A5044794520 @default.
• W3169396312 creator A5067066167 @default.
• W3169396312 creator A5073501391 @default.
• W3169396312 date "2021-06-02" @default.
• W3169396312 modified "2023-10-02" @default.
• W3169396312 title "Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis" @default.
• W3169396312 cites W2072926000 @default.
• W3169396312 cites W2345425230 @default.
• W3169396312 cites W2572897530 @default.
• W3169396312 cites W2622000437 @default.
• W3169396312 cites W2793239124 @default.
• W3169396312 cites W2796129073 @default.
• W3169396312 cites W2885371856 @default.
• W3169396312 cites W2888285761 @default.
• W3169396312 cites W2912943673 @default.
• W3169396312 cites W2918541059 @default.
• W3169396312 cites W2945302694 @default.
• W3169396312 cites W2971658527 @default.
• W3169396312 cites W2989520969 @default.
• W3169396312 cites W3015655457 @default.
• W3169396312 cites W4211170289 @default.
• W3169396312 cites W4211203343 @default.
• W3169396312 cites W4235489476 @default.
• W3169396312 doi "https://doi.org/10.3389/fmed.2021.678864" @default.
• W3169396312 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8208078" @default.
• W3169396312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34150809" @default.
• W3169396312 hasPublicationYear "2021" @default.
• W3169396312 type Work @default.
• W3169396312 sameAs 3169396312 @default.
• W3169396312 citedByCount "3" @default.
• W3169396312 countsByYear W31693963122023 @default.
• W3169396312 crossrefType "journal-article" @default.
• W3169396312 hasAuthorship W3169396312A5012912140 @default.
• W3169396312 hasAuthorship W3169396312A5014630057 @default.
• W3169396312 hasAuthorship W3169396312A5024129575 @default.
• W3169396312 hasAuthorship W3169396312A5027023070 @default.
• W3169396312 hasAuthorship W3169396312A5030777217 @default.
• W3169396312 hasAuthorship W3169396312A5039317523 @default.
• W3169396312 hasAuthorship W3169396312A5040219665 @default.
• W3169396312 hasAuthorship W3169396312A5044794520 @default.
• W3169396312 hasAuthorship W3169396312A5067066167 @default.
• W3169396312 hasAuthorship W3169396312A5073501391 @default.
• W3169396312 hasBestOaLocation W31693963121 @default.
• W3169396312 hasConcept C126322002 @default.
• W3169396312 hasConcept C142724271 @default.
• W3169396312 hasConcept C203092338 @default.
• W3169396312 hasConcept C204787440 @default.
• W3169396312 hasConcept C27081682 @default.
• W3169396312 hasConcept C2777575956 @default.
• W3169396312 hasConcept C535046627 @default.
• W3169396312 hasConcept C71924100 @default.
• W3169396312 hasConceptScore W3169396312C126322002 @default.
• W3169396312 hasConceptScore W3169396312C142724271 @default.
• W3169396312 hasConceptScore W3169396312C203092338 @default.
• W3169396312 hasConceptScore W3169396312C204787440 @default.
• W3169396312 hasConceptScore W3169396312C27081682 @default.
• W3169396312 hasConceptScore W3169396312C2777575956 @default.
• W3169396312 hasConceptScore W3169396312C535046627 @default.
• W3169396312 hasConceptScore W3169396312C71924100 @default.
• W3169396312 hasLocation W31693963121 @default.
• W3169396312 hasLocation W31693963122 @default.
• W3169396312 hasOpenAccess W3169396312 @default.
• W3169396312 hasPrimaryLocation W31693963121 @default.
• W3169396312 hasRelatedWork W2045151582 @default.
• W3169396312 hasRelatedWork W2082406232 @default.
• W3169396312 hasRelatedWork W2156283049 @default.
• W3169396312 hasRelatedWork W2316954211 @default.
• W3169396312 hasRelatedWork W2326094713 @default.
• W3169396312 hasRelatedWork W2427075784 @default.
• W3169396312 hasRelatedWork W2617939361 @default.
• W3169396312 hasRelatedWork W2761967325 @default.
• W3169396312 hasRelatedWork W3200621203 @default.
• W3169396312 hasRelatedWork W4210646529 @default.
• W3169396312 hasVolume "8" @default.
• W3169396312 isParatext "false" @default.
• W3169396312 isRetracted "false" @default.
• W3169396312 magId "3169396312" @default.
• W3169396312 workType "article" @default.